Glaukos Completes Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal

Aliso Viejo-based Glaukos Corp. is entering an ophthalmic market currently dominated by Tarsus Pharmaceuticals after completing Phase 2 enrollment. The Phase 2 study, which enrolled 275 patients, will evaluate a topical cream for the treatment of Demodex blepharitis, an inflammation of the eyelids caused by mites. It could compete with Irvine-based Tarsus’ Xdemvy, the first and only FDA-approved treatment for the disease. “Demodex blepharitis re…

Glaukos Completes Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Key Takeaways Glaukos completed patient enrollment of a phase 2 clinical trial evaluating GLK-321, its investigational drug candidate for the treatment of Demodex blepharitis. GLK-321 uses a patented, cream-based drug formulation applied to the outer surface of the eyelids to enable dropless, transdermal delivery of pharmaceutically active compounds. The phase 2 trial will evaluate safety, tolerability, and efficacy of three different dose lev…